$20.97
-5.9%Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.6M | -$14.8M | -$7.4M | -$3.7M | -$1.8M | -$924.6K | -$462.3K | -$231.1K | -$115.6K | -$57.8K |
| Maintenance CapEx | -$51.1K | -$25.6K | -$12.8K | -$6.4K | -$3.2K | -$1.6K | -$798 | -$399 | -$200 | -$100 |
| Owner Earnings | -$29.6M | -$14.8M | -$7.4M | -$3.7M | -$1.9M | -$926.2K | -$463.1K | -$231.5K | -$115.8K | -$57.9K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$27.4M | -$12.7M | -$5.9M | -$2.7M | -$1.3M | -$583.6K | -$270.2K | -$125.1K | -$57.9K | -$26.8K |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.